Table 2.
Profile of human immunodeficiency virus (HIV) infection and laboratory data of the study population by gender
| Variable | Male n (%) | Female n (%) | P |
|---|---|---|---|
| Drugs user (recreational and injecting drug)* | |||
| No | 394 (77.0) | 140 (89.7) | 0.0004 |
| Yes | 118 (23.0) | 16 (10.3) | |
| Antiretroviral therapy | |||
| No therapy | 413 (54.3) | 128 (52.7) | 0.028 |
| Monotherapy | 117 (14.4) | 22 (9.1) | |
| Dual therapy | 60 (7.9) | 25 (10.3) | |
| HAART | 170 (22.4) | 68 (28.0) | |
| TCD4 cell count† | |||
| <200 | 82 (36.1) | 34 (29.8) | 0.497 |
| 200–500 | 103 (45.4) | 58 (50.9) | |
| >500 | 42 (18.5) | 22 (19.3) | |
| Viral load‡ | |||
| Undetectable | 37 (22.0) | 13 (16.5) | 0.320 |
| <10,000 | 62 (36.9) | 28 (35.4) | |
| 10,000–30,000 | 12 (7.1) | 11 (13.9) | |
| >30,000 | 57 (33.9) | 27 (34.2) | |
HAART, highly active anti-retroviral therapy.
P values refer to Chi-square test.
*
Data available for 668 individuals.
†
Data available for 341 individuals (cells/mm3).
‡
Data available for 247 individuals (cp/ml of blood).